Aureus Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Aureus Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.25M	Buy	+9,511	New	+$1.26M	0.08%	102

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aureus Asset Management's NBIX Position: Q1 2026 in Review

Aureus Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 9,511 shares worth $1.25M. The stake represents 0.08% of the portfolio and ranks #102 among its holdings.

694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Aureus Asset Management held 9,511 shares of Neurocrine Biosciences worth $1.25M as of Q1 2026.
Neurocrine Biosciences was a new Aureus Asset Management position in Q1 2026.
Neurocrine Biosciences made up 0.08% of Aureus Asset Management's portfolio in Q1 2026, its #102 holding.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Aureus Asset Management's 13F filing for Q1 2026, filed 13 May 2026.